Wind data shows that on April 1, 2025, A-share Hong Kong stocks will recover significantly, and the trend of the innovative drug sector will attract attention, with the Science and Technology Innovation Pharmaceutical ETF (588860) and the Innovative Drug Industry ETF (516060) trading actively.

Recently, the State Food and Drug Administration released the "2024 Drug Evaluation Report". According to the report, in 2024, China will approve 48 Class 1 innovative drugs, covering nearly 20 therapeutic areas such as tumors, neurological diseases, endocrine system diseases and anti-infection.

The China Post Securities team said that the 2025 government work report clearly supports the upgrading of the whole chain of innovative drugs, and the maturity of AI-assisted R&D, ADC and other technologies will promote the industry to reduce costs and increase efficiency. In addition, the proportion of outbound licensing transactions of innovative drugs in China has increased from less than 5% in 2020 to 30% in 2024, and 16 licensing collaborations have been reached in the first two months of 2025, covering oncology, autoimmunity and other fields.

Great Wall Guorui Securities pointed out that the recent multiple policies and R&D progress in the pharmaceutical industry have released positive signals, and it is recommended to pay attention to innovative drugs and leading enterprises with outstanding internationalization capabilities to grasp structural opportunities. In terms of policy, the 2024 drug review report shows that the approval of innovative drugs remains efficient, and the policy combination is tilting from "cost control" to "encouraging innovation" with the optimization of the dynamic adjustment mechanism of medical insurance and the optimization plan of centralized procurement policy. It is recommended to lay out along three main lines: 1) innovative pharmaceutical companies with global multi-center clinical capabilities (oncology and autoimmune fields are preferred); 2) High-quality imitation enterprises with centralized procurement and pressure relief (focusing on cardiovascular and chronic diseases); 3) Overseas authorization of innovative drugs to fulfill the target. Cinda Securities believes that as the second quarter approaches, events such as medical insurance negotiations, the expected landing of the medical insurance category C catalog, and a number of important oncology drug clinical meetings are expected to become catalysts for a new round of innovative drug market. At the same time, we believe that most pharmaceutical sub-sectors have base pressure in the first quarter, and the performance of the pharmaceutical sector in the second quarter is expected to show a gradual recovery trend. On the whole, we are firmly optimistic about the development of AI medical and innovative drugs in the medium and long term, and we recommend focusing on the fertility-related industry chain, consumer medical direction and stocks with performance exceeding expectations in 2025Q1.

Related ETFs:

The SSE Sci-Tech Innovation Board Biomedical Index selects 50 securities of listed companies in the fields of biomedicine, biomedical engineering, bio-agriculture, biomass energy, and other biological industries with large market capitalization from the Sci-Tech Innovation Board as index samples, reflecting the overall performance of the securities of listed companies in the representative biomedical industry in the Sci-Tech Innovation Board market.

Wind data shows that as of March 31, 2025, the top 10 weighted stocks in the SSE Science and Technology Innovation Board Biomedical Index (000683) are United Imaging Healthcare (688271), BeiGene (688235), Huitai Medical (688617), Allist (688578), Baili Tianheng (688506), Zelgen Pharmaceutical (688266), MGI (688114), Junshi Biosciences (688180), Aibo Medical ( 688050), Tebao Biotechnology (688278), the top ten weighted stocks accounted for 51.35% of the total. (Note: The relevant stocks are only displayed as index constituent stocks and are not recommended as individual stocks.) )

As a highly flexible pharmaceutical ETF focusing on the science and technology innovation version, the Science and Technology Innovation Pharmaceutical ETF has a small-cap growth style; Outstanding hard science and technology attributes, focusing on medical innovative devices + innovative drugs; The management fee is 0.45%, which is the lowest level of ETFs in its category.

The

CSI Innovative Drug Industry ETF (516060) closely tracks the CSI Innovative Drug Industry Index, which selects no more than 50 of the most representative securities of listed companies from the securities of listed companies whose main business involves the research and development of innovative drugs as the index sample, so as to reflect the overall performance of the securities of listed companies in the innovative drug industry, covering five major fields: chemical drugs, biological drugs, pharmaceutical services, traditional Chinese medicine and medical business, with the research and development of innovative drugs as the core, which is an important tool for investors to participate in the pharmaceutical innovation track.

Wind data shows that as of March 31, 2025, the top 10 weighted stocks in the CSI Innovative Pharmaceutical Industry Index (931152) are WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Kelun Pharmaceutical (002422), Huadong Pharmaceutical (000963), Fosun Pharma (600196), Changchun High-tech (000661), Zhifei Biotech (300122), Pharmaron (300759), and BeiGene (688235). ), Tigermed (300347), the top ten weighted stocks accounted for 48.92%. (Note: The relevant stocks are only displayed as index constituent stocks and are not recommended as individual stocks.) )

Risk Warning: The fund manager manages and uses the fund property in accordance with the principles of due diligence, honesty and trustworthiness, prudence and diligence, but does not guarantee that the fund will be profitable, nor does it guarantee the minimum return. The Science and Technology Innovation Pharmaceutical ETF Fund is an equity fund, with higher risk and return than hybrid funds, bond funds and money market funds. The Fund is an index fund that primarily uses a full replication strategy to track the performance of the underlying index market, with similar risk-return characteristics to the underlying index and the stock market represented by the underlying index. Innovative drug industry ETFs are equity funds, with higher risk and return than hybrid funds, bond funds and money market funds. The Fund is an index fund that primarily uses a full replication strategy to track the performance of the underlying index market, with similar risk-return characteristics to the underlying index and the stock market represented by the underlying index. Investing in equity funds carries a greater risk of income fluctuations. Funds are risky, investors should carefully read the "Fund Contract", "Prospectus", "Fund Product Key Facts Statement" and other legal documents before investing in the fund, and choose investment varieties suitable for their own risk tolerance on the basis of a comprehensive understanding of the product situation, fee structure, charging standards of each sales channel and listening to the suitability opinions of the sales agency, and fund investment should be cautious.